Drug updated on 4/16/2024

Dosage FormOphtalmic solution (topical; 2.5 mg/mL [0.25%])
Drug ClassEctoparasiticides
Ongoing and
Completed Studies


  • Indicated for the treatment of Demodex blepharitis.

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Lotilaner (Xdemvy) is indicated for the treatment of Demodex blepharitis, showing significant improvements in key clinical indicators such as reductions in mite density, eradication within six weeks, reduction in collarettes, and erythema cure.
  • Two systematic reviews/meta-analyses were analyzed to gather information about Xdemvy's effectiveness and safety profile.
  • The studies included adults as participants but did not detail specific subgroup considerations; future research could benefit from stratifying results by these variables to determine if certain subgroups respond more favorably or if specific risks are associated with particular patient segments.
  • In terms of safety, both studies highlighted that lotilaner's safety profile was comparable to the control group with no significant increase in adverse events reported.
  • While direct comparisons to other treatments were not available in the studies provided, lotilaner showed substantial statistical benefits over placebo/vehicle groups, which suggests its potential superiority or at least viability as a safe and effective treatment option for Demodex blepharitis.
  • Both studies mention limitations regarding the heterogeneity of outcomes and recommend larger study populations for future research, along with direct comparisons with other treatments for Demodex blepharitis.

Product Monograph / Prescribing Information

Document TitleYearSource
Xdemvy (lotilaner) Prescribing Information.2023Tarsus Pharmaceuticals Inc., Irvine, CA

Systematic Reviews / Meta-Analyses